We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Aspireo Reports Somatoprim Phase I b Interim Data
News

Aspireo Reports Somatoprim Phase I b Interim Data

Aspireo Reports Somatoprim Phase I b Interim Data
News

Aspireo Reports Somatoprim Phase I b Interim Data

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Aspireo Reports Somatoprim Phase I b Interim Data"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Aspireo Pharmaceuticals Limited has announced results of an interim analysis of a phase I b study.

This single centre study is investigating the safety, side effect profile, as well as pharmacokinetic and pharmacodynamic profile of multiple ascending doses of Somatoprim in healthy male volunteers, when administered alone and in combination with octreotide.

The preliminary data confirms the excellent safety profile of Somatoprim, with the maximum tolerated dose not reached. No serious adverse events were reported.

The few reported adverse events were generally mild to moderate and transient.

Somatoprim also demonstrated a dose-dependent lowering effect on growth hormone (hGH), as shown by an analysis of the pharmacodynamic effect on hGH, when stimulated by growth hormone releasing hormone.

The interim analysis also supports the beneficial side effect profile of Somatoprim when compared to octreotide.

The company expects final data to be available in Q2 2013.

Advertisement